See more : Fennec Pharmaceuticals Inc. (FRX.TO) Income Statement Analysis – Financial Results
Complete financial analysis of PetVivo Holdings, Inc. (PETV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PetVivo Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- init innovation in traffic systems SE (0EWR.L) Income Statement Analysis – Financial Results
- GACM Technologies Limited (GATECH.BO) Income Statement Analysis – Financial Results
- Costco Wholesale Corporation (CTO.DE) Income Statement Analysis – Financial Results
- Speqta AB (publ) (SPEQT.ST) Income Statement Analysis – Financial Results
- Fangdd Network Group Ltd. (DUO) Income Statement Analysis – Financial Results
PetVivo Holdings, Inc. (PETV)
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 968.71K | 917.16K | 115.59K | 12.58K | 3.59K | 77.94K | 1.51K | 7.12K | 75.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.18K | 526.82K | 201.15K | 10.70K | 19.71K | 77.94K | 643.39K | 746.85K | 743.63K | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 739.53K | 390.35K | -85.57K | 1.88K | -16.12K | 0.00 | -641.88K | -739.72K | -668.63K | -1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 76.34% | 42.56% | -74.03% | 14.97% | -449.33% | 0.00% | -42,508.48% | -10,383.51% | -891.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.27M | 690.58K | 474.88K | 98.23K | 12.67K | 200.98K | 118.94K | 167.89K | 168.60K | 4.40K | 119.30K | 0.00 | 0.00 | 157.30K |
| General & Administrative | 6.69M | 5.02M | 3.15M | 1.77M | 1.23M | 3.60M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 103.68K |
| Selling & Marketing | 3.40M | 3.41M | 1.35M | 94.98K | 171.51K | 38.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.80K |
| SG&A | 10.09M | 8.43M | 4.50M | 1.86M | 1.40M | 3.64M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 105.48K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 559.54K | 646.92K | 2.17M | 16.23M | 3.16M | 0.00 | 24.44M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.36M | 9.12M | 4.97M | 1.96M | 1.97M | 4.49M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
| Cost & Expenses | 11.59M | 9.65M | 5.17M | 1.97M | 1.99M | 4.57M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
| Interest Income | 0.00 | 15.84K | 9.85K | 228.60K | 32.19K | 84.95K | 0.00 | 0.00 | 0.00 | 0.00 | 19.53K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 228.60K | 32.19K | 84.95K | 74.02K | 188.51K | 270.58K | 399.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 126.85K | 114.43K | 65.15K | 86.71K | 559.54K | 646.92K | 643.39K | 746.85K | 743.63K | 10.48K | 36.97M | 3.81K | 227.00 | 659.00 |
| EBITDA | -10.49M | -8.62M | -4.99M | -1.87M | -1.49M | -3.92M | -1.64M | -16.39M | -2.51M | -1.20M | -19.68K | -78.59K | -102.18K | -262.12K |
| EBITDA Ratio | -1,083.35% | -952.23% | -4,345.73% | -14,885.32% | -39,724.53% | -5,032.45% | -108,737.02% | -219,579.00% | -3,343.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.62M | -8.73M | -5.06M | -1.96M | -2.02M | -4.67M | -2.29M | -16.39M | -3.25M | -1.20M | -36.97M | -82.40K | -102.40K | -262.78K |
| Operating Income Ratio | -1,096.45% | -952.23% | -4,374.69% | -15,574.72% | -56,190.97% | -5,995.70% | -151,345.50% | -230,062.51% | -4,334.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -333.96K | 15.84K | 41.53K | -1.56M | -66.60K | -84.95K | -52.02K | -132.05K | -1.48M | -363.84K | -19.68K | -3.81K | -227.00 | -659.00 |
| Income Before Tax | -10.96M | -8.72M | -5.01M | -3.52M | -2.08M | -4.76M | -2.34M | -16.52M | -4.73M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
| Income Before Tax Ratio | -1,130.92% | -950.50% | -4,338.76% | -28,007.47% | -58,047.21% | -6,104.70% | -154,790.60% | -231,916.03% | -6,307.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.84K | -73.21K | 228.60K | 32.19K | 84.95K | 74.02K | -990.17K | -1.08M | 388.68K | -19.68K | 0.00 | 0.00 | 0.00 |
| Net Income | -10.96M | -8.70M | -4.94M | -3.75M | -2.11M | -4.76M | -2.34M | -15.53M | -3.65M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
| Net Income Ratio | -1,130.92% | -948.77% | -4,275.42% | -29,824.89% | -58,944.23% | -6,104.70% | -154,790.60% | -218,017.03% | -4,868.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
| EPS Diluted | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
| Weighted Avg Shares Out | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
| Weighted Avg Shares Out (Dil) | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the American Association of Equine Practitioners Convention on December 8-10, 2024
MINNEAPOLIS, MN, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will exhibit at the American Association of Equine Practitioners (“AAEP”) convention to...
PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript
PetVivo Holdings, Inc. (OTCPK:PETV) Q2 2025 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer Garry Lowenthal - Chief Financial Officer Conference...
PetVivo Reports Fiscal Q2 2025 Results
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024....
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 14, 2024...
PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the...
Accel Media International Celebrates 5-Year Anniversary With Expanded Billboard Access, Dynamic Taxi Tops, and Multi-Channel Media Solutions Through New to The Street
AMI continues to expand its media portfolio by adding programmable Taxi Tops and multiple billboards in Las Vegas, ensuring unmatched exposure for its clients. NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Accel Media International (AMI) proudly celebrates...
PetVivo Meets Growing Demand for Spryng™ with Appointment of Veterinary Surgeon, Kirsty Husby, as Senior Technical Services Veterinarian
Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals
Delisting of Securities of Liberty Resources Acquisition Corp.; Achari Ventures Holdings Corp. I; PetVivo Holdings, Inc.; Galera Therapeutics, Inc.; Clean Energy Special Situations Corp.; Capitalworks Emerging Markets Acquisition Corp.; AERWINS Technologies Inc.; Biolase, Inc.; Global Gas Corporation; Corner Growth Acquisition Corp.; Lucy Scientific Discovery Inc.; Chicken Soup for the Soul Entertainment, Inc.; Ideanomics, Inc.; NexImmune, Inc.; Shapeways Holdings, Inc.; QIWI plc;
ASLAN Pharmaceuticals Limited; Conn's, Inc.; 2U, Inc.; International Media Acquisition Corp.; Presto Automation, Inc.; and VBI Vaccines, Inc.; from The Nasdaq Stock Market ASLAN Pharmaceuticals Limited; Conn's, Inc.; 2U, Inc.; International Media Acquisition Corp.; Presto Automation, Inc.; and VBI Vaccines, Inc.; from The Nasdaq...
Scot Cave Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is...
Anthony Germinaro Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is...
Source: https://incomestatements.info
Category: Stock Reports